MedTrace Logo

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin

NCT01218204 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 287

Last updated 2019-07-16

Study results available
· View outcomes & findings →

Summary

This study investigates the safety, pharmacokinetics and effects of GSK1292263 when taken alone or when co-dosed with atorvastatin to subjects with dyslipidemia.

Conditions

  • Dyslipidaemias
  • Dyslipidemias

Interventions

DRUG

10mg atorvastatin

10mg

DRUG

80mg atorvastatin

80mg

DRUG

GSK1292263 Placebo

Placebo

DRUG

100mg GSK1292263

100mg

DRUG

300mg GSK1292263

300mg

DRUG

800mg GSK1292263

800mg

DRUG

10mg ezetimibe

10mg

OTHER

Washout

No interventions - washout period

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-14
Primary Completion
2011-06-29
Completion
2011-06-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01218204 on ClinicalTrials.gov